Protein kinase is the critical regulator of varied cellular functions, and are known widely for their increased affinity for targets in various pathological conditions. The kinase inhibitors’ pharmacology have developed tremendously over the previous 20 years, facilitating majority inhibitors to be orally available.
Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-pdf/2373
TTK is a kinase with dual specificity, which is able to phosphorylate both the tyrosine along with residues of serine/threonine. The gene is related with the cell proliferation, which is crucial for orientation of chromosome at centromere through mitosis and is needed for duplication of centrosome. It was discovered to be a crucial mitotic checkpoint protein to accurately segregate chromosomes through mitosis. They possess high utility for a therapeutic target within several areas of application including breast cancer, solid tumor, metastatic breast cancer, colorectal cancer, pancreatic ductal adenocarcinoma, prostate cancer, and others.
Global Dual Specificity Protein Kinase TTK Market – Dynamics
Rising incidence of several cancer types including breast cancer, solid tumor, metastatic breast cancer, prostate cancer, pancreatic ductal adenocarcinoma, colorectal cancer, among others is expected to accelerate the global dual specificity protein kinase TTK market growth. For instance, as per the Cancer Research UK, around 17 Mn new cancer cases are projected to be registered globally in 2018. Furthermore, according to the U.S. National Library of Medicine and National Institutes of Health (NIH), pancreatic ductal adenocarcinoma is amongst the most deadly cancers globally with highest prevalence rate found in North America and Western Europe whereas lower rate in Asia and Africa, in 2017, with 7.2 and 2.8 /100,000 incidence rate, respectively.
Rising pipeline molecules associated with dual specificity protein kinase TTK, as an intended therapy for several cancer types is expected to drive the global dual specificity protein kinase TTK market growth. The pipeline of dual specificity protein kinase TTK consists over 10 to 12 molecules, from which over 7 molecules are company developed and others are universities/institutes developed. For instance, Bayer AG, in 2017, in the U.S., completed trial studies of phase I for its Empesertib (BAY 1161909) pipeline molecule within solid tumors. Moreover, rising investments by pharma companies, have influenced the market growth.
Buy This Research Study Report With Flat US $2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2373
Global Dual Specificity Protein Kinase TTK Market – Regional Insights
Based on region, the global dual specificity protein kinase TTK market is segregated into North America, Latin America, Asia Pacific, Africa and Middle East. In 2017, North America gained the highest share in the global dual specificity protein kinase TTK market, due to increasing R&D activities within the segment of oncology in this region. Moreover, increasing prevalence of several cancer types is expected to drive the global dual specificity protein kinase TTK market growth within the region. For instance, in 2017, as per American Cancer Society, over 13% of the entire cancers within adults of age 20 years and above are the rare cancers having around 6/ 100,000 prevalence per year.
Furthermore, Asia pacific region is expected to register robust growth in the global dual specificity protein kinase TTK market during the forecast period, due to rising R&D activities of targeted therapies that are cancer-based along with government initiative for awareness of cancer within this region. For instance, an Australia-based non-profit organization – Rare Cancers Australia (RCA) is focusing to enhance the patients’ lives with less common or rare cancers through promoting the early diagnosis importance and rising treatment alternatives for the populace of Australia.
Global Dual Specificity Protein Kinase TTK Market – Competitive Landscape
Key players functioning in the global dual specificity protein kinase TTK market are Bayer AG, Les Laboratoires Servier SAS, Boston Pharmaceuticals, Nerviano Medical Sciences Srl, Pfizer Inc., and Netherlands Translational Research Center BV. Major players are focusing to adopt market strategies including novel product developments along with approvals of clinical trial, for retaining a dominant market position. For instance, Nerviano Medical Sciences and Servier, in September 2015, began their first human clinical study of the S 81694 (NMS-P153) drug. This drug is the mitotic checkpoint kinase (MPS1) inhibitor.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/dual-specificity-protein-kinase-ttk-market-2373
Global Dual Specificity Protein Kinase TTK Market – Taxonomy
Based on product type,
- Small Molecules to Inhibit Tyrosine Threonine Kinase for Oncology
- Small Molecules to Inhibit Mps1 for Breast Cancer
Based on the therapy area,
- Breast Cancer
- Solid Tumor
- Metastatic Breast Cancer
- Pancreatic Ductal Adenocarcinoma
- Prostate Cancer
- Colorectal Cancer
Based on end-user,
- Research Institutes & Universities
Based on geography,
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027